Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduct
Conclusion: The options for drugs to inhibit the platelet P2Y12 receptor for adenosine diphosphate are rapidly expanding. Ticagrelor has shown benefits in clinical trials. Its rapid onset of platelet inhibition and short half-life make it an attractive al...